List of Excipients in Branded Drug POTASSIUM IODIDE

Generic Drugs Containing POTASSIUM IODIDE

Company	Ingredient	NDC	Excipient
Mission Pharmacal Company	potassium iodide	0178-0314	BLACK RASPBERRY
Mission Pharmacal Company	potassium iodide	0178-0314	FD&C BLUE NO. 1
Mission Pharmacal Company	potassium iodide	0178-0314	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in POTASSIUM IODIDE?

# Of NDCs	Excipient
1	BLACK RASPBERRY
1	FD&C BLUE NO. 1
1	FD&C RED NO. 40

Potassium Iodide Excipient Strategy and Commercial Opportunities

Last updated: September 14, 2026

Potassium iodide (KI) is a low-cost, mature active pharmaceutical ingredient with limited composition-of-matter protection and low technical barriers to tablet production. Commercial value is concentrated in radiation-emergency stockpiles, government procurement, hospital supply, pediatric dose flexibility, extended shelf life, and reliable global distribution. The strongest product strategy is a stable, rapidly disintegrating oral dosage form with differentiated strengths, tamper-resistant packaging, and validated long-term stability.

What is the regulatory status of potassium iodide?

Potassium iodide is approved for thyroid blocking after exposure, or possible exposure, to radioactive iodine. It does not provide general radiation protection and does not replace evacuation, sheltering, or other emergency measures. The FDA recommends use only when public-health authorities direct it.[1]

Typical FDA emergency dosing is:

Population	Potassium iodide dose
Adults and adolescents over 12 years	130 mg
Children 3 to 12 years	65 mg
Children 1 month to 3 years	32.5 mg
Newborns to 1 month	16.25 mg

The product may be administered once daily for the duration specified by public-health authorities. Repeated administration requires medical oversight because excessive iodine exposure can cause thyroid dysfunction, particularly in neonates, older adults, and patients with thyroid disease.[1]

Which potassium iodide dosage forms are commercially relevant?

The main commercial dosage forms are:

1. 130 mg tablets for adults and older adolescents.
2. 65 mg scored tablets for children and adults who require a lower dose.
3. Oral solutions for pediatric, institutional, or administration-flexibility applications.
4. Bulk pharmaceutical-grade potassium iodide for compounding and manufacturing.

Tablets are generally the most attractive finished-product format because they offer low packaging cost, high stability, simple inventory management, and rapid distribution. Oral solutions have greater dosing flexibility but face higher risks from microbial control, container compatibility, evaporation, leakage, and dose-measurement errors.

What excipients are suitable for potassium iodide tablets?

Potassium iodide is highly water-soluble and can be formulated using conventional direct-compression or wet-granulation platforms. The excipient system should prioritize dose uniformity, mechanical strength, rapid disintegration, moisture control, and resistance to iodide oxidation.

Formulation function	Candidate excipient classes	Strategic purpose
Diluent	Microcrystalline cellulose, mannitol, lactose, dibasic calcium phosphate	Supports tablet weight, flow, and compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Enables rapid release after oral administration
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Sweetener or flavor	Sucralose, saccharin sodium, mannitol, fruit flavors	Improves pediatric acceptability
Coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide where permitted	Improves handling, identification, and moisture protection
Antioxidant or stabilizer	Product-specific systems, potentially including thiosulfate chemistry	May control iodine formation, subject to compatibility data

The final excipient selection must be supported by compatibility studies, impurity testing, dissolution, disintegration, assay, content uniformity, and accelerated and long-term stability data. Potassium iodide can oxidize to iodine under unfavorable conditions, producing discoloration and potency loss. Oxygen exposure, light, moisture, trace metals, and alkaline or acidic microenvironments should be evaluated during development.

Should potassium iodide tablets be direct-compressed?

Direct compression is usually the preferred first-line approach for a low-cost emergency tablet. It minimizes processing steps, lowers manufacturing cost, and supports rapid scale-up. The key technical risks are segregation, poor flow, low tablet weight, and inadequate content uniformity when the active is blended with a large excipient fraction.

A practical development path is:

• Use a high-flow diluent such as microcrystalline cellulose or mannitol.
• Add a superdisintegrant at a level that supports rapid breakup without excessive friability.
• Use low-shear blending to reduce segregation.
• Optimize lubricant concentration and blending time.
• Use opaque, high-barrier packaging for commercial stockpiles.
• Compare uncoated and film-coated tablets under accelerated stability conditions.

Wet granulation may improve uniformity and tablet strength but introduces water and additional thermal and drying exposure. That process should be selected only when direct compression cannot meet content-uniformity or mechanical-performance targets.

What formulations are protected by potassium iodide excipient strategy?

The strongest formulation differentiation is unlikely to come from ordinary use of standard excipients. Conventional tablet compositions are difficult to protect broadly because potassium iodide is an old, inexpensive active and many standard excipient combinations would be vulnerable to obviousness challenges.

More defensible formulation opportunities include:

• A low-dose pediatric tablet with validated subdivision or dispersibility.
• A rapidly disintegrating tablet that maintains stability during long-term stockpiling.
• A moisture-resistant tablet packaged for high-humidity climates.
• A unit-dose oral powder or dispersible tablet for emergency administration.
• A pediatric oral solution with controlled iodine formation and long shelf life.
• A dose-conversion platform that reduces administration errors between 16.25 mg, 32.5 mg, 65 mg, and 130 mg.
• A combination package containing age-specific strengths, dosing instructions, and administration devices.

A patent strategy should focus on measurable technical parameters, such as stability, dissolution, iodine impurity limits, disintegration time, packaging interaction, or a defined manufacturing process. Claims limited to "potassium iodide plus a conventional tablet excipient" would likely have limited commercial strength.

When does potassium iodide lose exclusivity?

Potassium iodide has no meaningful modern composition-of-matter exclusivity. The active ingredient has been used medically for decades, and commercial competition is primarily governed by manufacturing economics, regulatory approval, procurement access, and quality systems.

Exclusivity category	Commercial assessment
Composition-of-matter patent	Not commercially significant
New chemical entity exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	Product-specific and not a general KI barrier
Formulation patents	Possible but likely narrow
Method-of-use patents	Possible but difficult to make broad for established radiation-blocking use
Regulatory exclusivity	Depends on the specific approved application
Government procurement preference	Can be commercially important despite weak IP

Potassium iodide should therefore be evaluated as a regulated commodity drug rather than a patent-protected specialty product.

What is the Orange Book status of potassium iodide?

Potassium iodide products may appear in FDA approval and product databases depending on the product, dosage form, sponsor, and application pathway. Orange Book relevance is product-specific. An applicant should verify current listings, listed patents, therapeutic-equivalence ratings, and approval status before filing an ANDA or pursuing a Paragraph IV certification.[2]

The relevant legal point is that an Orange Book listing, if present for a specific approved product, does not create exclusivity for potassium iodide as an active ingredient. It can affect only the listed product and the patents associated with that application.

For most potassium iodide entrants, the regulatory pathway is likely to be:

• ANDA submission for a pharmaceutically equivalent product where a suitable reference product exists.
• NDA or other FDA pathway where the proposed product, formulation, strength, or labeling does not fit the ANDA framework.
• Separate state, federal, or foreign requirements for emergency stockpile procurement.

Are there Paragraph IV challenges or potassium iodide patent lawsuits?

Potassium iodide has a lower Paragraph IV risk profile than newer branded drugs because its active ingredient and core emergency use are mature. A potential ANDA applicant would still need to assess:

• Current Orange Book patents for the selected reference product.
• Patent certifications required under the Hatch-Waxman framework.
• Any formulation, packaging, or manufacturing patents.
• Pediatric dosing claims.
• Regulatory exclusivity attached to the reference application.
• Ongoing district-court or Federal Circuit litigation.

No broad, commercially material patent thicket is associated with potassium iodide as a molecule. Litigation risk is more likely to arise from product quality, contract disputes, procurement awards, labeling, or manufacturing compliance than from core composition-of-matter rights.

Settlement agreements are therefore less likely to define market entry than in high-value small-molecule markets. Any settlement involving a particular approved product would need to be reviewed against the product’s current listing and litigation record.

What manufacturing and intellectual-property barriers affect potassium iodide?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

Potassium iodide manufacturers must control:

• Assay and related iodine species.
• Heavy metals and elemental impurities.
• Moisture uptake.
• Powder flow and segregation.
• Tablet hardness, friability, and disintegration.
• Container-closure integrity.
• Long-term stability under high humidity.
• Batch traceability and emergency-release capacity.

For emergency procurement, the ability to produce large quantities on short notice can be more valuable than a novel formulation. Sponsors should maintain validated processes, redundant suppliers, and packaging capacity for multiple strengths.

Intellectual-property barriers

The most plausible IP assets involve:

• Moisture-resistant packaging configurations.
• Stable oral solutions.
• Specific excipient ratios linked to stability or rapid disintegration.
• Manufacturing methods that reduce iodine formation.
• Dose-flexible pediatric delivery systems.
• Combination emergency kits.

These claims should be built around reproducible performance data. Broad claims covering standard tablets are unlikely to create durable exclusivity.

What commercial opportunities exist for potassium iodide?

Government and public-health stockpiles

Government stockpiling is the clearest commercial opportunity. National and regional authorities may purchase KI for communities near nuclear facilities, emergency responders, hospitals, military organizations, and strategic reserves. The business model is contract-driven and can involve large but intermittent orders.

Competitive advantages include:

• Domestic or regional manufacturing.
• Ability to supply several strengths.
• Shelf-life extension data.
• Rapid surge capacity.
• Government-contract compliance.
• Secure packaging and serialized distribution.
• Low total cost per dose.

Hospital and institutional supply

Hospitals may require KI for emergency departments, pediatric services, radiology departments, and disaster-preparedness inventories. Unit-dose blister packs and clearly labeled age-specific strengths can reduce medication errors.

A hospital-focused product can differentiate through:

• Barcode-ready packaging.
• Unit-dose presentation.
• Scored 65 mg tablets.
• Pediatric oral syringes for solutions.
• Emergency-cart packaging.
• Electronic prescribing compatibility.
• Long dating and simple storage conditions.

Pediatric delivery

Pediatric dosing is a meaningful product-design opportunity because emergency KI dosing spans four age groups. A 65 mg scored tablet may allow flexibility, but splitting is not equivalent to a validated 32.5 mg or 16.25 mg product unless the tablet has been designed and tested for subdivision.

A pediatric strategy could include:

• 16.25 mg unit doses for neonates.
• 32.5 mg dispersible tablets.
• 65 mg scored tablets.
• A calibrated oral solution.
• A single package containing multiple age-appropriate strengths.

The commercial advantage is administration accuracy, not simply a lower tablet price.

International markets

International demand is affected by national nuclear policy, public-health procurement, local labeling requirements, and regional product registration. Geographic expansion may be attractive in Europe and Asia-Pacific, but iodine-blocking recommendations and national stockpile systems vary.

A global product needs:

• Country-specific emergency labeling.
• Local-language instructions.
• Stability data for hot and humid zones.
• Packaging suitable for government warehousing.
• Dose presentations aligned with local public-health guidance.
• Regulatory review of excipients and colorants.

How does potassium iodide compare with competing emergency products?

Potassium iodide has few direct pharmaceutical substitutes for radioactive-iodine thyroid blocking. Other radiation-countermeasure products address different toxicities or radiation mechanisms.

Product category	Primary role	Relationship to potassium iodide
Potassium iodide	Blocks thyroid uptake of radioactive iodine	Targeted thyroid protection
Prussian blue	Removes certain radioactive cesium and thallium	Different mechanism and exposure
Calcium or zinc DTPA	Binds plutonium, americium, and curium	Different radionuclides
General iodine supplements	Nutritional supplementation	Not an equivalent emergency product
Evacuation or sheltering	Reduces exposure	Not a pharmaceutical substitute

Potassium iodide should not be marketed as a general radiation antidote. Product labeling and public-health communications must preserve this distinction.[1,3]

What revenue exposure and launch scenarios exist?

Revenue is more likely to be episodic than prescription-driven. A sponsor should model three launch scenarios:

Scenario	Demand pattern	Commercial implication
Baseline preparedness	Hospital and government replenishment	Stable but limited annual volume
Procurement event	Large public contract or national stockpile purchase	High-volume, low-margin order
Emergency event	Rapid surge following a nuclear incident or credible threat	Capacity, allocation, and logistics dominate

Public pricing data are not sufficient to establish a single global market size because government contracts, private-label supply, and emergency procurement terms vary materially. Margin expansion is most plausible through packaging, differentiated pediatric products, contract manufacturing, and procurement reliability rather than through premium pricing for the active ingredient.

How strong is the potassium iodide patent estate?

The patent estate is weak for the active ingredient and potentially moderate for narrow delivery or stability innovations.

Asset type	Relative strength
Potassium iodide molecule	Very weak
Standard immediate-release tablet	Weak
Conventional excipient blend	Weak
Stable pediatric liquid	Moderate if supported by strong data
Moisture-resistant packaging	Moderate, usually narrow
Novel dispersible or unit-dose system	Moderate
Manufacturing process reducing iodine impurities	Moderate to strong if non-obvious and reproducible
Government supply qualification	Commercially important but not patent exclusivity

Freedom-to-operate analysis should focus on current formulation, packaging, manufacturing, and product-specific patents rather than historical patents on potassium iodide itself.

Key Takeaways

• Potassium iodide is a mature, low-cost drug with minimal active-ingredient exclusivity.
• Government stockpiles, hospital preparedness, and pediatric dosing are the primary commercial opportunities.
• Direct compression is the preferred initial tablet-development platform.
• Moisture, oxygen, light, iodine formation, and container compatibility are the main stability risks.
• Formulation patents are most credible when tied to measurable stability, disintegration, impurity, or dosing performance.
• A 65 mg scored tablet and age-specific unit-dose packaging can provide more practical value than a conventional premium tablet.
• Orange Book and Paragraph IV analysis must be conducted at the individual approved-product level.
• The main competitive barriers are regulatory compliance, procurement access, manufacturing capacity, and shelf-life performance.
• Biosimilar risk is not applicable because potassium iodide is a small-molecule inorganic salt, not a biologic.
• Commercial success depends more on supply reliability and emergency-contract execution than on patent exclusivity.

FAQs

Is potassium iodide a generic drug?

Potassium iodide is a mature active ingredient available through multiple manufacturers and product formats. Whether a specific product is legally classified as a generic depends on its FDA approval pathway and reference-product relationship.

Can potassium iodide be sold as an over-the-counter product?

Marketing status depends on the product, labeling, formulation, and FDA pathway. A sponsor should not assume that an unapproved supplement or iodine product has the same status as an FDA-approved potassium iodide emergency product.

What packaging is best for potassium iodide stockpiles?

High-barrier, light-protective unit-dose blisters or tightly controlled bottles are generally more suitable than low-barrier packaging. The final choice should be based on stability, moisture ingress, dose presentation, and government storage conditions.

Can potassium iodide be combined with Prussian blue?

They address different radioactive contaminants and should not be combined into one product without a defined medical rationale, compatible dosing, regulatory justification, and clinical or public-health support.

Is a potassium iodide oral solution more commercially valuable than a tablet?

The solution offers pediatric dosing flexibility but carries greater stability, microbial, packaging, and administration risks. Tablets usually provide better stockpile economics, while solutions may have value in specialized pediatric or institutional settings.

References

1. U.S. Food and Drug Administration. (2001). Potassium iodide as a thyroid blocking agent in radiation emergencies. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. World Health Organization. (2017). Iodine thyroid blocking: Guidelines for use in planning for and responding to a nuclear or radiological emergency. World Health Organization.

4. U.S. National Library of Medicine. (2024). DailyMed: Potassium iodide drug labels. National Library of Medicine.

5. United States Pharmacopeial Convention. (2024). USP-NF monograph: Potassium iodide. United States Pharmacopeial Convention.